Prehospital thrombolysis with reteplase: The Nijmegen/Rotterdam studyLAMFERS, Evert J. P; SCHUT, Astrid; HOOGHOUDT, Ton E. H et al.The American heart journal. 2003, Vol 146, Num 3, pp 479-483, issn 0002-8703, 5 p.Article

Direct action on the molecule is one of several mechanisms by which ultrasound enhances the fibrinolytic effects of reteplaseMADSEN HÄRDIG, Bjarne; PERSSON, Hans W; BERTIL OLSSON, S et al.Blood coagulation & fibrinolysis. 2006, Vol 17, Num 2, pp 105-112, issn 0957-5235, 8 p.Article

Efficacy of reteplase in poorly functioning hemodialysis cathetersFALK, A; SAMSON, W; URIBARRI, J et al.Clinical nephrology. 2004, Vol 61, Num 1, pp 47-53, issn 0301-0430, 7 p.Article

The efficacy and safety of reteplase for thrombolysis of hemodialysis catheters at a community and academic regional medical centerHYMAN, Gary; ENGLAND, Michael; KIBEDE, Sosena et al.Nephron. 2004, Vol 96, Num 2, pp c39-c42, issn 0028-2766Article

Reteplase for clearance of occluded venous cathetersOWENS, Larry.American journal of health-system pharmacy. 2002, Vol 59, Num 17, pp 1638-1640, issn 1079-2082Article

A fresh look at the molecular pharmacology of plasminogen activators : From theory to test tube to clinical outcomesSMALLING, R. W.American journal of health-system pharmacy. 1997, Vol 54, Num 22, pp S17-S22, issn 1079-2082, SUP1Conference Paper

Cloning, expression, and renaturation studies of reteplaseZHAO, Youchun; WANG GE; YANG KONG et al.Journal of microbiology and biotechnology. 2003, Vol 13, Num 6, pp 989-992, issn 1017-7825, 4 p.Article

The concept of equivalence and its application to the assessment of thrombolytic effectsHAMPTON, J. R.European heart journal. 1997, Vol 18, Num DEC, pp F22-F27, issn 0195-668X, SUPFConference Paper

Combination pharmacotherapy with reduced-dose fibrinolytic and platelet GP IIb/IIIa inhibitionBUSH, Howard S.The Journal of emergency medicine. 2003, Vol 25, Num 4, pp 421-426, issn 0736-4679, 6 p.Article

Effect of Reteplase^™ and PAI-1 antibodies on postoperative adhesion formation in a laparoscopic mouse modelBINDA, Maria Mercedes; HELLEBREKERS, Bart W. J; DECLERCK, Paul J et al.Surgical endoscopy. 2009, Vol 23, Num 5, pp 1018-1025, issn 0930-2794, 8 p.Article

Acute myocardial infarction complicated by pulmonary embolism after thrombolytic therapy : Problems in clinical managementKUCINSKY, Rastislac; GOLDHABER, Samuel; TAVEL, Morton E et al.Chest. 2005, Vol 128, Num 5, pp 3572-3575, issn 0012-3692, 4 p.Article

Antiangiogenic activity of a domain deletion mutant of tissue plasminogen activator containing kringle 2CARROLL, Veronica A; NIKITENKO, Leonid L; BICKNELL, Roy et al.Arteriosclerosis, thrombosis, and vascular biology. 2005, Vol 25, Num 4, pp 736-741, issn 1079-5642, 6 p.Article

Benefical effects of reteplase in combination with abciximab: Platelet/leukocyte interactions and coagulation systemSZABO, S; WALTER, T; ETZEL, D et al.International journal of clinical pharmacology research. 2003, Vol 23, Num 2-3, pp 37-40, issn 0251-1649, 4 p.Article

Survival outcomes 1 year after reperfusion therapy with either alteplase or reteplase for acute myocardial infarction : Results from the Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries (GUSTO) III TrialTOPOL, Eric J; OHMAN, E. Magnus; WHITE, Harvey D et al.Circulation (New York, N.Y.). 2000, Vol 102, Num 15, pp 1761-1765, issn 0009-7322Article

Current clinical use of reteplase for thrombolysis: A pharmacokinetic-pharmacodynamic perspectiveMARTIN, U; KAUFMANN, B; NEUGEBAUER, G et al.Clinical pharmacokinetics. 1999, Vol 36, Num 4, pp 265-276, issn 0312-5963Article

Prognostic implication of activated partial thromboplastin time after reteplase or half-dose reteplase plus abciximab : results from the GUSTO-V trialNALLAMOTHU, Brahmajee K; BATES, Eric R; LINCOFF, A. Michael et al.European heart journal. 2005, Vol 26, Num 15, pp 1506-1512, issn 0195-668X, 7 p.Article

ST-segment resolution 60 minutes after combination treatment of Abciximab with Reteplase or Reteplase alone for Acute myocardial infarction (30-day mortality results from the resolution of ST-segment after reperfusion therapy substudy)CURA, Fernando A; ROFFI, Marco; PASCA, Narcis et al.The American journal of cardiology. 2004, Vol 94, Num 7, pp 859-863, issn 0002-9149, 5 p.Article

Fibrinolysis for acute myocardial infarction: The future is here and nowARMSTRONG, Paul W; COLLEN, Désiré; ANTMAN, Elliott et al.Circulation (New York, N.Y.). 2003, Vol 107, Num 20, pp 2533-2537, issn 0009-7322, 5 p.Article

Hemodynamic effects of double bolus reteplase versus alteplase infusion in massive pulmonary embolismTEBBE, U; GRAF, A; KAMKE, W et al.The American heart journal. 1999, Vol 138, Num 1, pp 39-44, issn 0002-8703, 1Article

The role of thrombolytic drugs in the management of myocardial infarction : Comparative clinical trialsWEAVER, W. D.European heart journal. 1996, Vol 17, Num DEC, pp 9-15, issn 0195-668X, SUPFConference Paper

Reteplase infusion in the treatment of acute lower extremity occlusionsKIPROFF, Paul M; YAMMINE, Kabalan; POTTS, Jonathan M. S et al.Journal of thrombosis and thrombolysis. 2002, Vol 13, Num 2, pp 75-79, issn 0929-5305Article

Thrombolytic fibrin specificity influences activated partial thromboplastin time prolongation in vitroTSIKOURIS, J. P; JACKSON, K. C; FIKE, D. S et al.Blood coagulation & fibrinolysis. 2002, Vol 13, Num 8, pp 725-731, issn 0957-5235, 7 p.Article

The ideal fibrinolytic: can drug design improve clinical results?VAN DE WERF, F. J.European heart journal. 1999, Vol 20, Num 20, pp 1452-1458, issn 0195-668XArticle

Patency trials with reteplase (r-PA) : What do they tell us ?BODE, C; NORDT, T. K; PETER, K et al.The American journal of cardiology. 1996, Vol 78, Num 12A, pp 16-19, issn 0002-9149Conference Paper

Combination reperfusion therapy with abciximab and reduced dose reteplase : results from TIMI 14ANTMAN, E. M; GIBSON, C. M; VAN DER WIEKEN, R et al.European heart journal. 2000, Vol 21, Num 23, pp 1944-1953, issn 0195-668XArticle